Top Markets
#1 Akedo Akedo +58.47%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.71%
#4 Cross Cross +45.85%
#5 Black Phoenix Black Phoenix +34.29%
#6 Velvet Velvet +30.75%
#7 OVERTAKE OVERTAKE +19.61%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.83%
#9 Cap Cap +15.18%
#10 QANplatform QANplatform +14.92%
Coin of the day
Akedo Akedo
Innstillinger
Språk
NORSK
Valuta
USD
Tema
BNB Plus Corp. BNB Plus Corp.

BNB Plus Corp.

BNBX
Rangering i aksjer #38647
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a... BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Aksjekurs
$0.09
Sist synkronisert: 2026-07-28
Markedsverdi
$876.21K
Endring (1 dag)
0.00%
Endring (1 år)
-97.79%
Land
US
Handel BNB Plus Corp. (BNBX)

Kategori

Healthcare
Inntekter for BNB Plus Corp. (BNBX)
Inntekter i 2026 TTM: 0
Ifølge BNB Plus Corp. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for BNB Plus Corp. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE